Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth Opportunities
TORONTO and DALLAS, Aug. 11, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced preliminary unaudited revenues for the second quarter ended June 30, 2025, senior management changes, and the creation of a Perimeter Industry Advisory Board ("IAB").
Preliminary Unaudited Second Quarter 2025 Revenues
Unless otherwise indicated, all amounts in this press release are expressed in U.S. dollars.
Perimeter anticipates total revenue for the second quarter of 2025 to be approximately $500,000, representing year-over-year growth of approximately 100%. Sequentially, the Company expects that greater than 35% procedure growth will result in over 50% recurring revenue growth in Q2-2025 compared to Q1-2025. This was primarily driven by stronger current Perimeter S-Series system utilization, with significantly more interoperative OTC imaging procedures performed by existing surgeon users, and at a higher price per procedure.
For the six-month period ended June 30, 2025, total revenue is expected to be approximately $1.0 million, compared to $345,000 in the 6-month period ended June 30, 2024 and $846,000 for the full year ended December 31, 2024.
Gross margin is expected to be approximately 69% for the second quarter and 61% for the six-month period ended June 30, 2025, respectively.
"We are excited that the growing adoption, both in terms of new system placements and increased current device utilization, we saw during the first three months of the year continued through the second quarter," commented Adrian Mendes, Perimeter's Chief Executive Officer. "To put that into perspective, six-month 2025 revenue alone is estimated to surpass revenues for all of 2024. Now, as our sales pipeline continues to build, and with the Premarket Approval application for our next-generation Perimeter B-Series under review with the FDA, we anticipate a continuation of strong growth moving forward."
Further, Perimeter advised that it expects initial savings from its cost control efforts will result in an approximate 30% reduction in total operating costs, starting in Q3-2025.
These figures are preliminary and unaudited, and actual revenues may differ. Perimeter is providing this information due to planned investment community meetings to be held ahead of its Q2-2025 financial results release and conference call later this month.
Leadership Changes
Perimeter announced today the appointments of Abbey Goodman as Vice President, Sales, and Paolo DiPasquale as Vice President, Corporate Development, in a move designed to further position the Company for continued sales success and growth:
Ms. Goodman brings over 20 years of medical device sales experience, most recently serving as Profound Medical's Global Chief Commercial Officer. Prior to joining Profound, she progressed through a variety of senior sales leadership roles with Hologic, Novadaq Technologies, Covidien (now Medtronic), and DePuy Mitek. Ms. Goodman earned a BS in Biological Engineering from Louisiana State University.
Mr. DiPasquale brings a unique perspective as someone who has over 17 years of experience in the U.S. and Canadian capital markets across Equity Research, Institutional Equity, and Investment Banking at Canaccord Genuity and Stephens. Most recently, he served as Chief Strategy Officer of a gaming and marketing company, where he managed its successful capital raising strategy and go-public process on NASDAQ. Mr. DiPasquale is a graduate of Duquesne University with two majors: a BSc in Finance and a BSc in Investment Management.
In addition, Perimeter announced that Tom Boon has recently retired as Perimeter's Chief Operating Officer. Mr. Boon will continue to help guide the Company's commercial strategy through his membership on Perimeter's newly formed IAB (please see below).
"We are excited to welcome Abbey and Paolo to the Perimeter team. They bring deep expertise and leadership that will be critical as we advance our business," said Mr. Mendes. "At the same time, we want to thank Tom for his outstanding leadership and contributions to Perimeter. We look forward to continuing to work with him in his new capacity on our IAB."
Creation of Perimeter Industry Advisory Board
Perimeter also announces the creation of an IAB to support the Company's growth strategies across all products, channels and geographies. Chairing the IAB will be Diana Chan, Managing Director of BridgeGap Solutions Group. With over 20 years of experience in the medical device industry, Ms. Chan is a seasoned marketing leader dedicated to driving growth and innovation. She played a key role in MOLLI Surgical's journey, from building its brand presence and implementing growth strategies to its successful exit after three years of commercialization through its acquisition by Stryker Corporation. Currently, she provides advisory and mentorship in the medtech space through BridgeGap Solutions Group, a consultancy she founded to support organizations with limited resources in business and market development. Prior to MOLLI Surgical, she held executive positions at Medtronic, Bard, and Fresenius Medical Care. Ms. Chan received a BA in Administrative and Commercial Studies from Western University, and an MBA from the University of Notre Dame.
The full mandate and initial composition of the IAB will be announced at a later date.
Conference Call
Perimeter will report its second quarter 2025 financial and operating results after market close on August 26, 2025. Following the announcement, the Company will host a conference call and live audio webcast at 5:00 pm Eastern Time to discuss the results and provide a corporate update. To participate in the call, please dial 1-800-717-1738 or 1-646-307-1865. The conference call will also be broadcast live online through a listen-only webcast, which will be posted on the Investors section of the Company's website and archived for approximately 90 days.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that has recently been evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.
Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the Company's results for the three and six months June 30, 2025, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding management's views regarding the second quarter, the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT and the expected benefits of Perimeter's updated version of its ImgAssist AI are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis and Annual Information Form for the year ended December 31, 2024, which are available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
Financial Outlook
This press release contains a financial outlook within the meaning of applicable Canadian securities laws. The financial outlook has been prepared by management of the Company to provide an outlook for the Company's forecasted revenue for the three and six months ended June 30, 2025 and may not be appropriate for any other purpose. The financial outlook has been prepared based on a number of assumptions including the assumptions discussed under the heading "Forward-Looking Statements" herein. The actual results of the Company's operations for any period will likely vary from the amounts set forth in these projections and such variations may be material. The Company and its management believe that the financial outlook has been prepared on a reasonable basis. However, because this information is highly subjective and subject to numerous risks, including the risks discussed under the heading "Forward-Looking Statements" herein, it should not be relied on as necessarily indicative of future results.
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: [email protected]
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 minutes ago
- Cision Canada
Grown Rogue Reports Second Quarter 2025 Results
Pro Forma Revenue and Pro Forma Adjusted EBITDA, including New Jersey affiliate, ABCO Garden State LLC ("ABCO"), were $8.01 million and $1.82 million, respectively, up 4% and down 12% year-over-year, and up 8% and down 2% on an apples-to-apples basis, excluding the 2024 second quarter contributions from the termination of the Vireo services agreement. Continued ramp in our New Jersey cultivation operations' second full quarter of sales, ongoing growth investments in talent and overhead, and substantial pricing pressure in Oregon and Michigan impacted our state-level and overall margins. Oregon operations generated $3.08 million in revenue and $0.80 million in Adjusted EBITDA (26.1% margin), maintaining healthy margins despite a challenging pricing environment, with our ASPs on A-grade flower down 25% YoY. Michigan operations contributed $2.28 million in revenue and $0.78 million in Adjusted EBITDA (34.2% margin), maintaining healthy margins despite a challenging pricing environment, with our ASPs on A-grade flower down 26% YoY. New Jersey affiliate ABCO generated $2.65 million in revenue and $1.29 million in Adjusted EBITDA (48.6% margin), demonstrating continued operational progress and replicable execution of our cultivation platform. Reported IFRS revenue was $5.56 million, with Adjusted EBITDA of $0.53 million. MEDFORD, Ore., Aug. 12, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company, combining craft values with scaled production and disciplined execution, is pleased to report its second quarter 2025 financial results for the three months ended June 30, 2025. All financial information is provided in U.S. dollars unless otherwise indicated. Summary and Pro Forma Metrics (Q2 2025 vs. Q2 2024) (US $ in millions) – Pro Forma figures are non-IFRS measures. * Includes revenue from New Jersey (ABCO) which is not included in Grown Rogue Consolidated results ¹ Non-IFRS financial measure. See MD&A for further details and reconciliations Market Performance by State (Q2 2025 vs. Q2 2024) (US $ in millions) ¹ Non-IFRS financial measure. See MD&A for further details and reconciliations *New Jersey operations launched late 2024; no year-over-year comparison available Market Core KPIs (Q2 2025 vs. Q2 2024) * New Jersey operations launched late 2024; no year-over-year comparison available Management Commentary from CEO, Obie Strickler "We have seen pricing in Oregon and Michigan compress significantly over the last year. We want to be clear to investors about our perspective on this: we believe price normalization is a natural and healthy part of any market — especially in cannabis, where lower prices pull more consumers into safer regulated products. We also firmly believe Oregon and Michigan are not outliers but rather harbingers of what every market in the nation will eventually experience to similar degrees, albeit on different timelines. Even as pricing has come down, our teams continue to deliver profitability and attractive returns on capital. We recognize that pricing will be cyclical and that we do not control the overall market price. Instead, we focus on what we can control — executing at the highest levels possible to continue to elevate our craft. This means remaining a constantly improving team, particularly when it comes to driving cost efficiencies and enhancing flower quality. From my lens, our team has executed on these priorities exceptionally well. We are applying everything we have learned in Oregon and Michigan in New Jersey, and we are excited to continue to apply these learnings to the other growth engines in our business. We are underway with construction of Phase 1 of our affiliate Illinois cultivation facility, and we are evaluating Minnesota as our next potential organic, new build market. With our administrative support, our National Director of Cultivation was awarded pre-approval for a Minnesota cultivation license, and we are currently evaluating real estate options. Minnesota has the key attributes that align with our organic growth model, most notably, a limited supply of craft-quality indoor flower. We're excited about the potential to bring Grown Rogue's flower-forward approach to customers in a state we came to know well during our advisory agreement with Vireo. While expanding into new markets, we've also made intentional investments in corporate overhead and team capabilities. We're bringing in the right talent and systems to ensure that as we grow, we preserve the operational discipline and culture that set Grown Rogue apart. These investments may put short-term pressure on margins, but they position us to capitalize on the opportunities we see emerging across the industry — including several distressed opportunities currently under evaluation. We are also monitoring recent federal discussions on potential rescheduling. We support measures that advance legalization, decriminalization, and reduce regulatory complexity. From a business standpoint, we'd welcome any changes that ease the regulatory burden of operating in the cannabis industry, although we do not expect any of the potential near-term decisions being discussed to materially impact our operations or growth strategy." "A confluence of factors, most notably increased competition, limited access to incremental capital and substantial debt and lease burdens, has created a window of significant financial and operational distress across the industry, with overbuilt and expensive cultivation infrastructure often at the center. We view this period of industry distress as a real opportunity — our flower-forward model is built to thrive in competitive, price-sensitive markets. By staying low-cost, high-quality, and disciplined, we're positioned to capture share where others are struggling, and we plan to lean into these opportunities. One of the reasons I joined the Grown Rogue team was my personal experience navigating complex and immature state-level supply chains and recognizing that the efficient production of quality flower is the economic engine of the industry — amplifying profits across the supply chain during periods of high pricing and providing resilience when markets grow more competitive. Distressed and restructuring transactions tend to be slow and complex, so it's hard to predict exact timing or the scale of what we might accomplish — but we'll be disappointed if this isn't a meaningful contributor to our growth over the next 18–24 months. Looking ahead, we remain laser-focused on executing our core organic growth strategy — expanding in New Jersey, advancing in Illinois, and positioning ourselves to enter Minnesota if the opportunity aligns. At the same time, we're prepared to leverage our operational expertise into distressed opportunities. I'm confident in the strong foundation we're building to support our future growth." Management Commentary from CFO, Andrew Marchington "Financially, we remain in a strong and flexible position – our core operations in Oregon and Michigan continue to generate healthy cash flow, and New Jersey is already contributing meaningfully while still early in its scale-up. As a reminder, because our New Jersey operations are through an affiliate, their results aren't consolidated in our IFRS financials. Instead, we provide Pro Forma Revenue and Adjusted EBITDA as supplemental measures – to give investors a better view of our total economic interest. We've included a reconciliation to reported IFRS results below for clarity." Reconciliation of Reported to Pro Forma Results (US$ in millions) Pro Forma revenue and Pro Forma Adjusted EBITDA are non-IFRS financial measures that include the results of the Company's New Jersey affiliate, ABCO Garden State LLC ("ABCO"), which are not consolidated in the Company's IFRS financial statements. Management believes these measures provide investors with additional insight into the Company's economic interest in all operating assets. Further details and reconciliations for non-IFRS financial measures are provided in the Company's MD&A for the three and six months ended June 30, 2025, which will be filed today on SEDAR+ ( and EDGAR ( Conference Call and Webcast Information Grown Rogue will release its financial statements and Management's Discussion and Analysis for the three- and six-month periods ended June 30, 2025, after market close on Tuesday, August 12, 2025. To further enhance investor disclosure, the Company will also post an updated Company Overview presentation to its website and host a conference call and webcast shortly after the release. Conference Call Details Date: Tuesday August 12, 2025 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Webcast: Register Dial-in: 1-800-836-8184 (Toll-Free in North America) A telephone replay of the conference call will be available until 19 August 2025, by dialing (+1) 888 660 6345 and using replay code: 33641# The webcast will be archived on Grown Rogue's Investor Relations website for approximately 90 days following the call. For assistance, please contact: [email protected] About Grown Rogue Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a flower-forward cannabis company rooted in Oregon's Rogue Valley, a region known for its deep cannabis heritage and commitment to quality. With operations in Oregon, Michigan, and New Jersey—and expansion underway in Illinois— Grown Rogue specializes in producing designer-quality indoor flower. Known for exceptional consistency and care in cultivation, our products are valued by retailers, budtenders, and consumers alike. By blending craft values with disciplined execution, we've built a scalable, capital-efficient platform designed to thrive in competitive markets. We believe sustained excellence in cannabis flower production is the engine of the industry's supply chain—and our competitive advantage. For more information about Grown Rogue, please visit Three months ended Three months ended Six months ended Six months ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 $ $ $ $ Revenue Product sales 5,354,033 7,109,563 10,732,496 13,380,867 Service revenue 205,500 608,566 403,500 991,736 Total revenue 5,559,533 7,718,129 11,135,996 14,372,603 Cost of goods sold Cost of finished cannabis inventory sold (3,226,744) (3,567,522) (6,150,265) (6,340,207) Costs of service revenue - (59,632) - (159,701) Gross profit, excluding fair value items 2,332,789 4,090,975 4,985,731 7,872,695 Realized fair value loss amounts in inventory sold (559,544) (1,020,633) (1,078,709) (1,948,112) Unrealized fair value gain amounts on growth of biological assets 528,245 305,250 651,011 708,664 Gross profit 2,301,490 3,375,592 4,558,033 6,633,247 Expenses Amortization of property and equipment (Note 8) 119,159 211,293 233,294 466,345 General and administrative (Note 19) 2,380,489 3,008,543 4,683,637 5,027,867 Share option and restricted stock unit expense 674,734 28,186 1,442,343 84,371 Total expenses 3,174,382 3,248,022 6,359,274 5,578,583 Income (loss) from operations (872,892) 127,570 (1,801,241) 1,054,664 Other income (expense) Interest expense (157,283) (79,636) (275,739) (169,323) Accretion expense (368,258) (378,404) (588,391) (760,067) Other income (49,575) 29,522 569,308 46,498 Interest income 393,669 162,312 782,129 261,609 Unrealized gain (loss) on derivative liability (Notes 10.5, 11) 2,895,393 (7,546,164) 5,738,641 (13,206,204) Unrealized gain (loss) on warrants asset (168,162) 663,459 (1,340,654) 1,956,307 Loss on equity investment in associate (Note 6.1) (1,957) - (81,584) - Total other income (expense), net 2,543,827 (7,148,911) 4,803,710 (11,871,180) Gain (loss) from operations before taxes 1,670,935 (7,021,341) 3,002,469 (10,816,516) Income tax (Note 20) (251,077) (552,481) (502,069) (923,006) Net income (loss) 1,419,858 (7,573,822) 2,500,400 (11,739,522) Other comprehensive income (items that may be subsequently reclassified to profit & loss) Currency translation gain (loss) (6,547) (5,132) 1,288 (7,872) Total comprehensive income (loss) 1,413,311 (7,578,954) 2,501,688 (11,747,394) Gain (loss) per share attributable to owners of the parent – basic 0.01 (0.04) 0.01 (0.06) Weighted average shares outstanding – basic 246,988,149 210,438,579 237,209,594 196,811,444 Gain (loss) per share attributable to owners of the parent – diluted 0.01 0.01 0.01 0.01 Weighted average shares outstanding – diluted 256,532,400 243,741,268 244,244,594 215,111,968 Net income (loss) for the period attributable to: Non-controlling interest 99,131 109,472 182,131 140,200 Shareholders 1,320,727 (7,683,294) 2,318,269 (11,879,722) Net income (loss) 1,419,858 (7573,822) 2,500,400 (11,739,522) Comprehensive income (loss) for the period attributable to: Non-controlling interest 99,131 109,472 182,131 140,200 Shareholders 1,314,180 (7,688,426) 2,319,557 (11,887,594) Total comprehensive income (loss) 1,413,311 (7,578,954) 2,501,688 (11,747,394) Unaudited Condensed Consolidated Statements of Financial Position (US$ in millions) June 30, 2025 December 31, 2024 $ $ ASSETS Current assets Cash and cash equivalents (Note 18) 9,252,242 4,682,221 Accounts receivable, net (Note 18) 2,096,742 1,596,912 Biological assets (Note 3) 1,883,901 1,554,622 Inventory (Note 4) 4,504,265 4,769,776 Prepaid expenses and other assets 826,180 864,009 Notes receivable (Note 6.2) 8,217,783 7,189,635 Total current assets 26,781,113 20,657,175 Warrant asset (Note 13.1) 3,515,141 4,855,795 Other investments (Note 6.1) 1,728,779 1,810,363 Notes receivable (Notes 6.2) 2,765,431 2,613,969 Property and equipment (Note 8) 11,713,154 11,870,220 Intangible assets and goodwill (Note 9) 1,257,668 1,257,668 Deferred tax asset (Note 20) 317,241 250,620 TOTAL ASSETS 48,078,527 43,315,810 LIABILITIES Current liabilities Accounts payable and accrued liabilities 1,533,678 2,107,619 Current portion of lease liabilities (Note 7) 960,945 736,453 Current portion of long-term debt (Note 10) 1,057,319 227,679 Current portion of convertible debentures (Note 11) - 1,945,226 Current portion of business acquisition consideration payable (Note 5) 543,030 536,881 Derivative liability (Notes 10.5.1, 11.2) 119,778 12,504,175 Income tax payable 1,606,452 1,907,177 Total current liabilities 5,821,202 19,965,210 Lease liabilities, net of current portion (Note 7) 4,551,220 4,475,490 Long-term debt, net of current portion (Note 10) 6,593,748 1,001,681 Business acquisition consideration payable, net of current portion (Note 5) 1,560,370 1,693,540 Other non-current liabilities (Note 20) 657,627 269,883 TOTAL LIABILITIES 19,184,167 27,405,804 EQUITY Share capital (Note 12) 48,021,463 38,499,491 Shares issuable 51,382 - Contributed surplus (Notes 13 and 14) 9,998,062 9,025,541 Accumulated other comprehensive loss (124,642) (125,930) Accumulated deficit (30,522,274) (32,847,334) Equity attributable to shareholders 27,423,991 14,551,768 Non-controlling interests (Note 23) 1,470,369 1,358,238 TOTAL EQUITY 28,894,360 15,910,006 TOTAL LIABILITIES AND EQUITY 48,078,527 43,315,810 Unaudited Condensed Consolidated Statements of Cash Flow (US$ in millions) Grown Rogue Adjusted EBITDA Reconciliation (US$ in millions) Six months ended June 30 June 30 Adjusted EBITDA Reconciliation 2025 ($) 2024 ($) Net income (loss), as reported 2,500,400 (11,739,522) Add back realized fair value amounts included in inventory sold 1,078,709 1,948,112 Deduct unrealized fair value gain on growth of biological assets (651,011) (708,664) Add back amortization of property and equipment included in cost of sales 964,606 1,004,759 3,892,704 (9,495,315) Add back interest and interest accretion expense, as reported 864,130 929,391 Add back amortization of property and equipment, as reported 233,294 466,345 Deduct unrealized gain/add back unrealized loss on derivative liability, as reported (5,738,641) 13,206,204 Deduct unrealized gain on warrants asset, as reported 1,340,654 (1,956,307) Loss of equity method investment in associate 81,584 2,177 Interest income (782,129) (261,609) Other income (569,308) (46,498) Add back income tax expense, as reported 502,069 923,006 EBITDA (175,643) 3,767,394 Costs associated with acquisition of Golden Harvests 60,000 488,000 Share based compensation 1,442,343 84,371 New production location startup costs - 154,628 Nonrecurring legal and transaction costs - 177,641 Adjusted EBITDA 1,326,700 4,672,034 Segmented Adjusted EBITDA – Six months ended June 30, 2025 (US$ in millions) Notes: The Company's "aEBITDA," or "Adjusted EBITDA," is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines "EBITDA" as the Company's net income or loss for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on change in fair value of derivative liabilities, the effects of fair-value accounting for biological assets and inventory, as well as other non-cash items and items not representative of operational performance as reported in net income (loss). Adjusted EBITDA is defined as EBITDA adjusted for the impact of various significant or unusual transactions. The Company believes that this is a useful metric to evaluate its operating performance. The Company defined "Pro Forma Adjusted EBITDA" as the combined Adjusted EBITDA of the Company plus the Adjusted EBITDA of New Jersey (ABCO), with any intercompany transactions eliminated. "Pro forma Revenue" is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines "Pro forma Revenue" as combined revenue of the Company plus revenue of New Jersey (ABCO), an affiliate which is accounted for as an equity method investment, with any intercompany revenues eliminated. Non-IFRS Financial Measures EBITDA, Adjusted EBITDA, Pro Forma Adjusted EBITDA and Pro Forma Revenue are non-IFRS measures and do not have standardized definitions under IFRS. The Company has also provided unaudited pro-forma financial information, which assumes that operations which will be consolidated in the future are consolidated in the current reported periods. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. Accordingly, the following information provides reconciliations of the supplemental non-IFRS financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS. Forward-Looking Statements Disclaimer This press release contains statements which constitute "forward ‐ looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward ‐ looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward ‐ looking information is not based on historical facts but instead reflect the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward ‐ looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward ‐ looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Company's public disclosure documents filed on Sedar. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward ‐ looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward ‐ looking information except as otherwise required by applicable law. The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States through its indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company's business are disclosed in the Company's Listing Statement filed on its issuer profile on SEDAR+ at Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. SOURCE Grown Rogue International Inc.
Cision Canada
3 minutes ago
- Cision Canada
Denison Announces Offering of US$250 Million of Convertible Senior Notes
TORONTO, Aug. 12, 2025 /CNW/ - Denison Mines Corp. (TSX: DML) (NYSE AMERICAN: DNN) ("Denison" or the "Company") announces that it is offering convertible senior unsecured notes due 2031 (the "Notes") in an aggregate principal amount of US$250 million (the "Offering"). The Company expects to grant the initial purchasers of the Notes an option for a period of 13 days, beginning on, and including the date on which the Notes are first issued, to purchase up to an additional US$37.5 million aggregate principal amount of Notes. View PDF version View PDF The Company intends to use the net proceeds from the Offering for expenditures to support the evaluation and development of the Company's uranium development projects, including the Wheeler River Uranium Project and general corporate purposes. Additionally, the Company intends to pay the purchase price for the capped call transactions described below with a portion of the net proceeds from the Offering or from existing cash on hand. The Notes will be senior unsecured obligations of the Company and will accrue interest at a rate payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2026 and will be convertible into common shares of the Company (the "Shares"), cash or a combination of Shares and cash, at the Company's election. The Notes will mature on September 15, 2031, unless earlier repurchased, redeemed or converted in accordance with their terms. Prior to June 15, 2031, the Notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, the Notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The interest rate, the initial conversion rate and other terms of the Notes will be determined by Denison and the initial purchasers and will depend on market conditions at the time of pricing of the Offering. Denison will have the right to redeem the Notes in certain circumstances and holders will have the right to require Denison to repurchase their Notes upon the occurrence of certain events. In connection with the Offering, Denison expects to enter into privately negotiated cash-settled capped call transactions with one or more of the initial purchasers of the Notes, their respective affiliates and/or other financial institutions (the "capped call counterparties"). The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of Shares that will initially underlie the Notes, assuming the initial purchasers do not exercise their option to purchase additional Notes. The capped call transactions are expected generally to reduce potential economic dilution upon conversion of the Notes and/or offset any cash payments that Denison could be required to make in excess of the principal amount of any converted Notes upon conversion thereof, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional Notes, Denison expects to use the net proceeds from the sale of additional Notes for general corporate purposes and additionally, the Company intends to use the net proceeds from the sale of the additional Notes or existing cash on hand to fund the cost of entering into additional capped call transactions with the capped call counterparties. In connection with establishing their initial hedges of the capped call transactions, the capped call counterparties have advised Denison that they or their respective affiliates expect to enter into various derivative transactions with respect to the Shares concurrently with, or shortly after, the pricing of the Notes, and may unwind these various derivative transactions and purchase Shares in open market transactions shortly after the pricing of the Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Shares or the Notes at that time. In addition, the capped call counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Shares and/or purchasing or selling the Shares or other of Denison's securities in secondary market transactions following the pricing of the Notes and prior to the maturity of the Note (and are likely to do so during any observation period related to a conversion of a Note). This activity could also cause or avoid an increase or a decrease in the market price of the Shares or the Notes, which could affect a noteholder's ability to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of the Notes, it could affect the number of Shares and value of the consideration that noteholders will receive upon conversion of the Notes. The Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange and the NYSE American, and there can be no assurance as to whether, when or on what terms the Offering may be completed. The Notes issued in connection with the Offering and the Shares issuable upon the conversion of Notes will be subject to a statutory hold period in accordance with applicable securities legislation. The Company intends to rely on the Exemptions for Eligible Interlisted Issuer in accordance with section 602.1 of the TSX Company Manual. The Notes and the Shares issuable upon the conversion thereof have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), registered under any state securities laws, or qualified by a prospectus in any province or territory of Canada. The Notes and the Shares may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration under the Securities Act. The Notes will be offered only to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act). Offers and sales in Canada will be made only pursuant to exemptions from the prospectus requirements of applicable Canadian provincial and territorial securities laws. This press release is neither an offer to sell nor the solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer to sell or solicitation of an offer to buy, or a sale of, the Notes or any other securities in any jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Denison Denison is a uranium mining, exploration and development company with interests focused in the Athabasca Basin region of northern Saskatchewan, Canada. The Company has an effective 95% interest in its flagship Wheeler River Uranium Project, which is the largest undeveloped uranium project in the infrastructure rich eastern portion of the Athabasca Basin region of northern Saskatchewan. In mid-2023, a feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have the potential to be competitive with the lowest cost uranium mining operations in the world. Permitting efforts for the planned Phoenix ISR operation commenced in 2019 and are nearing completion with approval of the project's Environmental Assessment ("EA") received from the Province of Saskatchewan and Canadian Nuclear Safety Commission hearing dates set in the fall of 2025 for Federal approval of the EA and project construction license. Denison's interests in Saskatchewan also include a 22.5% ownership interest in the McClean Lake Joint Venture ("MLJV"), which includes unmined uranium deposits (with the mining at the McClean North deposit via the MLJV's Surface Access Borehole Resource Extraction ("SABRE") mining method having commenced in July 2025) and the McClean Lake uranium mill (currently utilizing a portion of its licensed capacity to process the ore from the Cigar Lake mine under a toll milling agreement), plus a 25.17% interest in the Midwest Joint Venture's Midwest Main and Midwest A deposits, and a 70.55% interest in the Tthe Heldeth Túé ("THT") and Huskie deposits on the Waterbury Lake Property. The Midwest Main, Midwest A, THT and Huskie deposits are located within 20 kilometres of the McClean Lake mill. Taken together, Denison has direct ownership interests in properties covering ~384,000 hectares in the Athabasca Basin region. Additionally, through its 50% ownership of JCU (Canada) Exploration Company, Limited ("JCU"), Denison holds additional interests in various uranium project joint ventures in Canada, including the Millennium project (JCU, 30.099%), the Kiggavik project (JCU, 33.8118%), and Christie Lake (JCU, 34.4508%). In 2024, Denison celebrated its 70th year in uranium mining, exploration, and development, which began in 1954 with Denison's first acquisition of mining claims in the Elliot Lake region of northern Ontario. The Toronto Stock Exchange and NYSE American LLC neither approve nor disapprove the information contained in this press release. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Certain information contained in this press release constitutes 'forward-looking information' within the meaning of the applicable United States and Canadian legislation, concerning the business, operations and financial performance and condition of Denison. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as 'potential', 'plans', 'expects', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes', or the negatives and/or variations of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' 'be taken', 'occur' or 'be achieved'. In particular, this press release contains forward-looking information pertaining to the following: statements relating to the Offering, including the option to purchase additional Notes, if any, the terms of the Notes, the anticipated timing for closing of the Offering, the anticipated use of proceeds and the intention to enter into capped call transactions; and expectations regarding Denison's joint venture ownership interests and agreements with third parties. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Denison to be materially different from those expressed or implied by such forward-looking statements. Denison believes that the expectations reflected in this forward-looking information are reasonable but no assurance can be given that these expectations will prove to be accurate and results may differ materially from those anticipated in this forward-looking information. For a discussion in respect of risks and other factors that could influence forward-looking events, please refer to the factors discussed in Denison's Annual Information Form dated March 28, 2025 under the heading 'Risk Factors' or in subsequent quarterly financial reports. These factors are not, and should not be construed as being, exhaustive. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. Any forward-looking information and the assumptions made with respect thereto speaks only as of the date of this press release. Denison does not undertake any obligation to publicly update or revise any forward-looking information after the date of this press release to conform such information to actual results or to changes in Denison's expectations except as otherwise required by applicable legislation.
Cision Canada
3 minutes ago
- Cision Canada
AI-Enhanced Competitive Intelligence Key to Secure Market Position in 2025, Says Info-Tech Research Group
With markets shifting faster and competitors adapting at record speed, AI-enhanced competitive intelligence platforms are more vital than ever for detecting early signals, identifying emerging threats, and guiding strategic pivots. By accelerating data collection, analysis, and real-time monitoring, these platforms enable organizations to act quickly and with greater precision. The global IT research and advisory firm's latest blueprint, Competitive Intelligence Software Selection Guide, outlines key selection criteria and a structured process for IT leaders to choose tools that deliver measurable value in an increasingly competitive, tech-first landscape. TORONTO, Aug. 12, 2025 /CNW/ - As competitive landscapes change at an unprecedented pace, where advantage can be won or lost within weeks, organizations are under pressure to identify market shifts early and act decisively. Info-Tech Research Group's recent research findings show that AI-enhanced competitive intelligence (CI) software has become critical for anticipating competitor moves, adjusting strategies, and protecting market share. By automating data collection, enabling real-time monitoring, and providing predictive analytics, these platforms help leaders act with speed and precision. In its new Competitive Intelligence Software Selection Guide, the global IT research and advisory firm notes that while most leading vendors offer similar core features, buyers should focus on data sources, output, usability, price, and differentiators that align with their unique requirements. The firm's guide also addresses common barriers such as budget limitations, reliance on outdated or inaccurate data, and the lack of consistent processes for storing and sharing intelligence. Info-Tech suggests a structured approach for IT and business leaders to define their unique CI requirements, identify a shortlist of vendors, and prepare for implementation. "Organizations that focus solely on feature lists risk missing the factors that truly drive competitive advantage," says Joanne Correia, a principal research director at Info-Tech Research Group."As the CI selection guide outlines, by prioritizing the right data sources, practical usability, and outputs that map directly to business goals, leaders can select a CI platform that supports both immediate needs and future growth." Info-Tech's guide also examines the key trends shaping the CI software market, including AI and machine learning for automation and predictive insights, increased reliance on social media and online data, cloud-based solutions for scalability and collaboration, and a heightened focus on cybersecurity and compliance. How to Select the Right Competitive Intelligence Software Info-Tech's Competitive Intelligence Software Selection Guide outlines the key challenges that organizations face, which include limited resources for CI staff, large volumes of outdated or inaccurate data, ineffective processes for sharing insights, and missed opportunities that slow growth and reduce market share. The firm's resource introduces a three-phase methodology for CIOs to ensure that IT and organizational leaders align on objectives, evaluate solutions against high-value use cases, and guide the selection of a platform that delivers measurable outcomes: Phase 1 – Understand CI Software Capabilities and Trends The first phase is to establish the foundation, which includes defining what CI software is, reviewing both standard and differentiating features, and examining market trends such as AI-driven automation, the use of social media data for monitoring, the shift to scalable cloud solutions, and the integration of advanced cybersecurity. This stage typically involves CI leads, product or marketing managers, and key contributors from IT and strategy teams. The goal is to reach agreement on the software's scope, must-have capabilities, and top-level use cases. Phase 2 – Define Requirements In the second phase, the core selection team, which often includes those involved in Phase 1, identifies requirements related to the organization's highest-value use cases. This step centers on completing Info-Tech's CI Vendor Evaluation Workbook, which can also support RFI, RFQ, or RFP processes to ensure vendors submit targeted and relevant responses. The result is a clear, organization-specific set of criteria for evaluating potential solutions. Phase 3 – Select a Vendor The final phase sharpens the focus on the shortlist, where the selection team conducts structured demos with top candidates that also serve as investigative interviews. Info-Tech recommends limiting demos to four vendors, using a scripted scenario based on high-value requirements, and challenging vendors to adapt visualizations, modify datasets, or test collaboration features on the spot. This approach keeps the evaluation grounded in real-world needs while avoiding "vendor glitz and glamour shows." The phase ends with making the final selection, planning the implementation, and, if necessary, using the firm's contract review services to assist with negotiation. By following this structured approach, organizations can ensure their CI investment delivers measurable business outcomes. The resource includes supporting resources, such as analyst insights and contract review considerations, to help teams make informed vendor decisions. For exclusive and timely commentary from Info-Tech's experts, including Joanne Correia, and access to the complete Competitive Intelligence Software Selection Guide, please contact [email protected]. About Info-Tech Research Group Info-Tech Research Group is one of the world's leading research and advisory firms, serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services, and SoftwareReviews for software buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact [email protected].
